Hyperion DeFi (NASDAQ: HYPD - Get Free Report) and Zelira Therapeutics (OTCMKTS:ZLDAF - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. Valuation and Earnings This table compares Hyperion DeFi
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has secured a major funding milestone after its HOPE® 1 special purpose vehicle (SPV) signed definitive...
Shares of Zelira Therapeutics Limited (OTCMKTS:ZLDAF - Get Free Report) were up 13.9% during mid-day trading on Monday. The stock traded as high as $0.2660 and last traded at $0.2660. Approximately 171 shares were traded during trading, a decline of 82% from the average daily volume of 973 shares. The stock had previously closed
Zelira Therapeutics Limited (OTCMKTS:ZLDAF - Get Free Report)'s share price dropped 4.4% during mid-day trading on Wednesday. The stock traded as low as $0.2056 and last traded at $0.2056. Approximately 228 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 936 shares. The stock had previously closed
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is well placed to generate further growth in cash flow and revenue via its diversified income streams, with a suite of new products launched in H1 FY2022. The company generated quarterly cash receipts of $0.341 million in Q2 FY2022 underpinned by sales of SprinjeneCBD and consulting payments, relatively stable to Q1 FY2022's $0.362 million.
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has received a cash refund of A$1.292 million under the Australian Federal Government's Research and Development Tax Incentive Scheme. The funds received will be used to support Zelira's portfolio of products recently launched in global markets and to advance its ongoing clinical development programs.
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has received US$250,000 of its upfront non-refundable, non-contingent licensing fee of US$1 million from DRCN Holdings LLC, with the remaining US$750,000 expected to be received in the first quarter of 2022. The global leader in the research and development of clinically validated cannabinoid medicines had successfully demonstrated enhanced dissolution of cannabinoids using its enhanced distillate capture and dissolution matrix (EDCDM) and signed a foundation licensing deal for this proprietary technology.
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF)'s open-label dose-escalation trial results in chronic non-cancer pain patients have been published in the peer-reviewed journal Pain And Therapy. The trial, undertaken by The St Vincent's Hospital Melbourne (SVHM) research team led by the coordinating investigator Associate Professor Yvonne Bonomo in conjunction with Emyria Ltd (ASX:EMD), examined the pharmacokinetics, safety and tolerability of escalating doses of a medicinal cannabis product in patients with chronic non-cancer pain (CNCP).
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is expanding into the growing New Zealand cannabinoid-based medicines market by way of a five-year exclusive distribution agreement with NUBU Pharmaceuticals. The agreement with NZ's largest medicinal cannabis distribution company furthers Zelira's global commercialisation strategy to grow the global footprint of its Pharmaceutical (Rx) portfolio.
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), which develops clinically validated cannabis medications, has secured ethics approval for a Phase 2a clinical trial to assess the effectiveness of its licensed patented cannabinoid formulation, ZTL-106, in treating patients with chronic pain. Licensee Levin Health is sponsoring the trial at La Trobe University's Sport and Exercise Medicine Research Centre (Melbourne, Australia) under an agreement struck in June 2021.
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has opened new pathways to develop pharmaceutical-grade cannabidiol capsules and tablets with its proprietary Enhanced Distillate Capture and Dissolution Matric (EDCDM) technology. The EDCDM technology solves a non-uniformity problem that causes cannabidiol distillate to separate from the powder bed when attempting to create solid oral dosage forms such as capsules and tablets.
Zelira Therapeutics Ltd quarterly reads as a long list of highlights, which is testament to the work it is doing in the development of clinically validated cannabinoid medicines. The company has not only achieved a record for cash receipts, it has achieved 16% growth on the previous quarter as sales of SprinjeneCBD continue to track well.
Zelira Therapeutics Ltd has raised a total of US$5 million from a US-based family office fund to accelerate its growth initiatives. Zelira is a global leader in the research and development of clinically validated cannabinoid medicines and its initiatives include: Clinical development and ongoing trials in Australia and the US; Additional licensing for Zelira Rx products and technologies; Commercialisation of RAF FIVE™ products with a focus on rapid market penetration; and Expansion of Zelira's SprinjeneCBD footprint in the US and emerging global CBD markets.
Zelira Therapeutics Ltd's research and development (R&D) and commercialisation programs are expected to lead to the launch of a suite of new cannabinoid-based products over FY22. In FY21, the global medicinal cannabis company focused on expanding commercialisation activities and revenue generation from new clinically validated products.
PHILADELPHIA, Sept. 23, 2021 /PRNewswire/ -- Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a global leader in the research and development of clinically validated cannabinoid medicines, is pleased to announce the US launch of the Zelira Dermatology Business' first product line, RAF FIVE™, through its dermatology subsidiary Ilera Derm LLC ("Zelira Dermatology").
Zelira Therapeutics Ltd, a leading global medicinal cannabis company, has launched its new line of CBD-based acne and skin products, RAF FIVE™. Developed in partnership with Harvard-trained and US board-certified cosmetic dermatologist Dr Karyn Grossman and noted drug development chemist Dr Brian Warrington, the RAF FIVE™ line of products consists of five acne treatments using a proprietary formulation incorporating CBD.
Zelira Therapeutics Ltd has expanded into Europe via the large and growing German cannabinoid-based medicines market through an exclusive distribution agreement with Adjupharm GmbH, a German subsidiary of IM Cannabis Corp. The five-year agreement marks the first time ZLD has expanded its cannabis interests outside of the Australian and US markets, with minimum order quantities totalling over A$4 million, with A$98,000 guaranteed within the first year.
Zelira Therapeutics Ltd continues to focus on the expansion of commercialisation activities and revenue generation from its new clinically tested products, with the strategy expected to lead to the launch of a suite of new cannabinoid-based products over FY22. Commercialisation plans are focused on generating revenues from the multiple products it has launched into the Australian and US markets.
Zelira Therapeutics Ltd has capped off the 2021 financial year with record cash receipts as it looks ahead to product launches later this year. The cannabinoid medicines developer finished the June quarter with A$311,000 in cash receipts — up 38% on the March quarter's A$225,000 result.
Zelira Therapeutics (ASX:ZLD) (OTCMKTS:ZALDF) has secured Institutional Review Board (IRB) approval for a pain observational trial to take place in the US. The cannabinoid medicines developer is set to test its patent-protected product against a big pharmaceutical company's multi-billion-dollar revenue drug.